Found: 21
Select item for more details and to access through your institution.
Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 719, doi. 10.1007/s00262-021-03031-1
- By:
- Publication type:
- Article
Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 589, doi. 10.1007/s00262-021-03005-3
- By:
- Publication type:
- Article
Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 727, doi. 10.1007/s00262-021-03032-0
- By:
- Publication type:
- Article
Correction to: Chemotherapy: a double‑edged sword in cancer treatment.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 737, doi. 10.1007/s00262-021-03029-9
- By:
- Publication type:
- Article
ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 645, doi. 10.1007/s00262-021-03022-2
- By:
- Publication type:
- Article
The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 705, doi. 10.1007/s00262-021-03026-y
- By:
- Publication type:
- Article
Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 601, doi. 10.1007/s00262-021-03019-x
- By:
- Publication type:
- Article
Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 661, doi. 10.1007/s00262-021-03021-3
- By:
- Publication type:
- Article
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 579, doi. 10.1007/s00262-021-03018-y
- By:
- Publication type:
- Article
An immune-related prognostic signature for thyroid carcinoma to predict survival and response to immune checkpoint inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 747, doi. 10.1007/s00262-021-03020-4
- By:
- Publication type:
- Article
Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 637, doi. 10.1007/s00262-021-03017-z
- By:
- Publication type:
- Article
A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 675, doi. 10.1007/s00262-021-03016-0
- By:
- Publication type:
- Article
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 627, doi. 10.1007/s00262-021-03014-2
- By:
- Publication type:
- Article
Transcriptomic signatures of tumors undergoing T cell attack.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 553, doi. 10.1007/s00262-021-03015-1
- By:
- Publication type:
- Article
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 689, doi. 10.1007/s00262-021-03009-z
- By:
- Publication type:
- Article
Chemotherapy: a double-edged sword in cancer treatment.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 507, doi. 10.1007/s00262-021-03013-3
- By:
- Publication type:
- Article
Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 565, doi. 10.1007/s00262-021-03011-5
- By:
- Publication type:
- Article
A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 529, doi. 10.1007/s00262-021-03007-1
- By:
- Publication type:
- Article
Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 541, doi. 10.1007/s00262-021-03002-6
- By:
- Publication type:
- Article
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 613, doi. 10.1007/s00262-021-02982-9
- By:
- Publication type:
- Article